Filing Flows

Filing Flows › Companies › Beta Bionics › Cash flow

Beta Bionics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$14.6M in Q3 2026 · −$66.0M over twelve months

Operating cash flow−$12.3M
Capital spending−$2.3M
Free cash flow−$14.6M
Cash conversion cycle162 days

Analysis

In Q3 2026, Beta Bionics generated −$12.3M of operating cash flow and spent $2.3M on capital projects, leaving free cash flow of −$14.6M. That is $4.6M less than in Q3 2025 (−$10.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$59.4M; the largest uses were operating cash flow ($59.4M), other investing ($58.1M), capital spending ($6.6M); besides operations, cash came from other financing ($167M); the cash balance rose by $43.1M.

Operating cash flow was −$12.3M against net income of −$24.4M. The largest differences: accrued liabilities +$7.0M, stock-based pay +$6.7M, receivables −$2.6M.

Its cash conversion cycle was 162 days (receivables 50 + inventory 142 − payables 30).

Free cash flow

Beta Bionics: free cash flow by quarterBeta Bionics: free cash flow by quarter−$14.8MQ4 2024−$20.3MQ1 2025−$15.4MQ2 2025−$10.0MQ3 2025−$10.5MQ4 2025−$25.2MQ1 2026−$15.7MQ2 2026−$14.6MQ3 2026
Operating cash flow less capital spending.
Beta Bionics: operating cash flow against capital spendingBeta Bionics: operating cash flow against capital spendingOperating cash flowCapital spending−$14.3M$561KQ4 2024−$20.0M$333KQ1 2025−$13.6M$1.8MQ2 2025−$8.7M$1.3MQ3 2025−$8.6M$1.9MQ4 2025−$23.8M$1.4MQ1 2026−$14.6M$1.0MQ2 2026−$12.3M$2.3MQ3 2026
Latest (Q3 2026): Operating cash flow −$12.3M, Capital spending $2.3M.

Capital allocation, year by year

Beta Bionics: where the cash came from (up) and went (down), by fiscal yearBeta Bionics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2023: Operating cash flow −$32.4MFY2023: Shares issued $101MFY2023: Asset sales $4KFY2023: Capital spending −$402K$101MFY2023FY2024: Operating cash flow −$48.3MFY2024: Shares issued $59.7MFY2024: Asset sales $50KFY2024: Capital spending −$3.4M$59.8MFY2024FY2025: Operating cash flow −$50.9MFY2025: Shares issued $199MFY2025: Capital spending −$5.3M$199MFY2025
Over these 3 years operating cash flow totalled −$132M; the largest uses were operating cash flow ($132M) and capital spending ($9.1M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$240M
Debtnone
Net cash$240M
Cash runway3.6 years

Beta Bionics is burning cash: its operations consume cash, a free cash flow of −$66.0M a year at the current rate against $240M of cash and investments: a runway of about 3.6 years before any new financing.

Where the cash came from and went

Beta Bionics: sources (+) and uses (−) of cash, Q3 2026Beta Bionics: sources (+) and uses (−) of cash, Q3 2026Other financing$162MOther investing−$112MCash drawn (+) / kept (−)−$37.2MOperating cash flow−$12.3MCapital spending−$2.3MShares issued$1.8M
Beta Bionics: sources (+) and uses (−) of cash, TTM to Q3 2026Beta Bionics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$167MOperating cash flow−$59.4MOther investing−$58.1MCash drawn (+) / kept (−)−$43.1MCapital spending−$6.6M

From profit to cash

Beta Bionics: net income to operating cash flow, Q3 2026Beta Bionics: net income to operating cash flow, Q3 2026Net income−$24.4MDepreciation & amortization$892KStock-based pay$6.7MReceivables−$2.6MInventory$1.3MPayables−$352KAccrued liabilities$7.0MDeferred revenue$191KPrepaid and other assets−$530KOperating cash flow−$12.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20265014230162
Q2 20264816527187
Q1 20265418329207
Q4 20254114733155
Q3 20253914330152
Q2 20254014029151
Q1 20255415133172

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$12.3M−$2.3M$1.8M−$37.2M−$14.6M
Q2 2026−$14.6M−$1.0M—−$14.1M−$15.7M
Q1 2026−$23.8M−$1.4M$623K$1.4M−$25.2M
Q4 2025−$8.6M−$1.9M$1.1M$6.9M−$10.5M
Q3 2025−$8.7M−$1.3M$2.7M−$3.4M−$10.0M
Q2 2025−$13.6M−$1.8M$42K$7.4M−$15.4M
Q1 2025−$20.0M−$333K$196M−$12.0M−$20.3M
Q4 2024−$14.3M−$561K$37K−$13.0M−$14.8M

Beta Bionics: income statement and cash flow

Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%. The chart follows the revenue to costs, profit and cash.

Beta Bionics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.